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May 20081120 AbstractsEndovascular versus open repair of abdominal aortic aneurysms in the
Medicare population
Schermerhorn ML, O’Malley AJ, Javeri A, et al. N Engl J Med 2008;358:
464-74.
Conclusions:Endovascular aortic aneurysm repair (EVAR) has a lower
short-term mortality rate and lower complication rates than open repair of
abdominal aortic aneurysm (AAA). The survival advantage is most durable
among older patients.
Summary:The authors sought to provide long-term population-based
data comparing open vs EVAR. The authors used propensity score-matched
cohorts of Medicare beneficiaries who underwent AAA repair from 2001 to
2004, with follow-up until 2005. Perioperative complications and deaths as
well as long-term survival, rupture, and reinterventions were compared in
the two groups. Each cohort included 22,830 matched patients undergoing
open repair of AAA. The average age was 76 years and 20% were women.
Perioperative mortality was lower after EVAR than open repair (1.2% vs
4.8%, P .001). Mortality reductions increased with age. There was a 2.1%
difference for patients aged 67 to 69 years and an 8.5% difference favoring
EVAR for patients aged 85 years or older (P .001). Survival at 3 years was
similar in patients undergoing open repair and EVAR. Rupture was more
common in the EVAR group by 4 years than in the open repair cohort (1.8%
vs 0.5%, P  .001). Reintervention related to AAA was also more common
in the EVAR group (9.0% vs 1.7%, P  .001). By 4 years, surgery for
laparotomy-related complications was more likely among patients who had
undergone open repair (9.7% vs 4.1%, P  .001). Hospitalization without
surgery for bowel obstruction or abdominal wall hernia was also more
common among the patients undergoing open repair (14.2%) vs EVAR
(8.1%, P  .001).
Comment:The unique feature of this study is the population analyzed.
With the exception of perhaps increased survival benefit for older patients
with EVAR, the authors’ results are neither unique nor unexpected. The
study indicates that complex medical technologies can be rapidly adapted
and widely instituted with good results.
Incidence of deep vein thrombosis related to peripherally inserted
central catheters in children and adolescents
Dubois J, Rypens F, Garel L, et al. CMAJ 2007;177:1185-90.
Conclusion:Deep venous thrombosis (DVT) of the upper extremities
is unusual in children and adolescents treated with peripherally inserted
central catheters (PICC).
Summary: The authors sought to determine and characterize the
incidence and risk factors for DVT associated with PICC in a pediatric
population. This was a prospective study of consecutive patients referred to
a radiology department in a tertiary care university-affiliated hospital for
insertion of a PICC. Patients were eligible for this study if they were aged
18 years, weighed 2.5 kg, and had successful insertion of a PICC
between June 2004 andNovember 2005. Patients were systematically tested
for factor V Leiden and factor II mutation G20210A. Platelet counts and
D-dimer levels were recorded. Assessments were also made of catheter-
related infection, catheter dysfunction, length of time the catheter was in
place, infusion of hyperosmolar solutions, and infusion of blood products
through the catheter. The primary outcome variable was the occurrence of
complete or partial DVT. DVT was determined with a protocol that speci-
fied ultrasound examinations on days 2, 4, 7, 17, 21, and 28 after insertion
of the catheter. Ultrasound examinations were also performed every month
until the catheter was removed. Upper extremity phlebography was per-
formed before and at removal of the catheter. No data were collected on
management and follow-up of upper extremity DVT in this study.
Of 728 patients that were eligible for this study, 490 were excluded
primarily for reasons of lack of informed consent, the catheter needing to be
inserted outside normal working hours, and referral from other hospitals.
The study ultimately included 238 patients, and 24 of them were also
subsequently excluded primarily for noncompliance with protocol require-
ments. This left 214 patients (101 girls, 113 boys) retained for analysis.
Complete or partial DVT occurred in 20 patients, an incidence of 93.5/
1000 patients and 3.85/1000 catheter-days. Only one case of PICC-
associated DVT was symptomatic. With univariable analysis, the only factor
associated with DVT was the presence of the factor II mutation G20210A
(odds ratio, 7.08; 95% confidence interval, 1.11-45.15; P  .04). The
overall rate of DVT related to PICC lines was 9.3%.
Comment:Despite the relative high incidence of DVT associated with
peripherally inserted central catheters, the incidence is lower than that
reported with centrally inserted venous catheters. Because only one of the
patients with DVT was symptomatic, the study argues that objective diag-nosis of DVT in patients with upper extremity catheters must be used to
determine the true incidence of this complication.
Venous thromboembolism and subsequent hospitalisation due to acute
arterial cardiovascular events: A 20-year cohort study
Sorensen HT, Horvath-Puho E, Pedersen L, et al. Lancet 2007;370:
1773-79.
Conclusion: Patients with venous thromboembolism (VTE) have an
increased long-term risk of arterial cardiovascular events.
Summary: There are conflicting data with respect to whether VTE is
associated with an increased risk of arterial cardiovascular events. To help
clarify discrepant studies in previous publications, the authors sought to
investigate the risk of arterial cardiovascular events in patients with VTE.
This was a 20-year population-based cohort study. Data were obtained from
nationwide Danish medical databases. Patients with known cardiovascular
disease were excluded from this study. The authors then assessed the risk of
stroke and myocardial infarction (MI) in 25,199 patients with deep venous
thrombosis (DVT), 16,925 patients with pulmonary embolism (PE), and
163,566 controls. In patients with DVT, the relative risks (95% confidence
interval) were 1.6 (1.35-1.91) for MI and 2.19 (1.85-2.60) for stroke 1
year after the thrombotic event. Similarly, in patients1 year after a PE, the
relative risks were 2.60 (2.14-3.14) for MI and 2.93 (2.34–3.66) for stroke.
During the next 20 years of follow-up, patients with VTE had 20% to 40%
increased risk for arterial cardiovascular events. There was no difference in
relative risk in patients with provoked vs unprovoked DVT and PE.
Comment: The etiology for the apparent association of atherosclerotic
events with VTE is unclear. With the exception of obesity, there is not
consistent evidence that venous and atherosclerotic diseases share common
risk factors. Perhaps a common prothrombotic mechanism, such as endo-
thelial damage or inflammation, accounts for a potential shared etiology
between VTE and arterial ischemia. There are, after all, other conditions
such as hyperhomocysteinemia and antiphospholipid antibody syndrome
that exemplify disorders that have both arterial and venous thromboembolic
features.
Beneficial effects of dalteparin on haemostatic function and local tissue
oxygenation in patients with diabetes, severe vascular disease, and foot
ulcers
Kalani M, Silveira A, BlombackM, et al. Thrombosis Res 2007;120:653-61.
Conclusion: Local skin oxygenation, as measured by transcutaneous
oxygen tension (TcPO2) and laser Doppler fluxmetry, is improved with
dalteparin in patients with diabetes, peripheral arterial disease (PAD), and
chronic foot ulcers.
Summary: Patients with diabetes appear to have a state of fibrinolytic
dysfunction and hypercoagulation that may contribute to disturbances in
skin microcirculatory function with resulting impaired healing of foot ulcers.
The authors have previously reported improved outcome of patients with
chronic foot ulcers and diabetes who were treated with dalteparin (Diabetes
Care 2003;26:2575-80). In this study, they sought to investigate the
mechanisms of the effects of dalteparin on haemostatic function and skin
microcirculation.
This was a prospective, randomized, double-blind, placebo-controlled
trial. The study randomized 87 patients with PAD, diabetes, and chronic
foot ulcers to treatment with once daily subcutaneous injections of 5000 U
of dalteparin (n 44) or placebo (n 43). Treatment continued until ulcer
healing or for a maximum of 6 months. Plasma fibrinogen, fibrin gel
structure (measured by permeability coefficient and fiber mass/length ra-
tio), prothrombin fragment 12 antigen, plasminogen activator inhibitor-1
activity, and tissue plasminogen activator antigen were analyzed before
randomization and at the end of treatment. Skin microcirculation was
assessed with laser Doppler fluxmetry and TcPO2.
Measurements of permeability coefficient, fiber mass/length ratio,
tissue plasminogen activator, and TcPO2 were higher (P  .05) with
treatment with dalteparin compared with placebo. Baseline plasma fibrino-
gen and the permeability coefficient significantly correlated with TcPO2.
Comment: Patients with diabetes have impaired healing. Although
much of this may be due to neuropathy, microcirculatory abnormalities have
long been postulated as contributing to poor healing in patients with
diabetes. Some of the microcirculatory abnormalities now appear responsive
to dalteparin, and there is some suggestion these effects may have clinical
relevance. Work in this area is still very preliminary, but it makes sense to
target the microcirculation as a site for possible intervention in patients with
diabetes and foot ulcers.
